big ideas for global investors Search
   Member Access       Sign-up       Newsfeeds        Companies        Stock Directories       Research       Video       Funding   

Zacks Small-Cap Research Updates Coverage on OxySure Systems (OTCQB: OXYS) - Video Research Alert on

Ideas get bigger when you share them...

Vancouver, British Columbia - (Newsfile Corp. - May 1, 2014) ( newswire) Zacks Small-Cap Research has updated coverage on OxySure Systems (OTCQB: OXYS). Following the release of the 4th quarter and full year results for the period ending December 31, 2013, analyst Jason Napodano has reiterated his target price of $1.50, a premium of 142% to the $0.62 price on April 16th, the day the report was issued.

Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner has produced a "video research alert" about OxySure based on this report. If this link is not enabled, please visit and enter "OxySure" in the search box.

If you cannot view the video above, please visit:

Revenues in the 4th quarter totaled $540,000, up 612% from the same period in 2012. Revenues far exceed expectations, as the anticipated dramatic slowdown in military orders during the fourth quarter of 2013 thanks to the government shutdown and sequester that occurred in November 2013, had little if any effect on revenues.

According to the Zacks' report, OxySure is doing some really neat stuff with the military, including working with the Navy on an emergency escape breathing device and with the SEAL team on providing oxygen for high-altitude jumps.

Analyst Jason Napodano stated, "OxySure is branching out beyond just first-aid devices like the Model 615, and we do not think investors have come to grips with the potential for smaller, more compact devices for battlefield use being developed right now by the company."

For those of you that are new to the OxySure story, the company has pioneered a safe and easy to use solution to produce medically pure oxygen from inert powders, eliminating the need for a pressurized gas tank.

The company's Model 615 has FDA 510k clearance for over the counter sale, giving the company a clear advantage over oxygen systems reliant on pressurized oxygen tanks, which require a prescription. Users simply plug in the mask, turn the knob, and place the mask over the nose and mouth. The Model 615 has quickly gained adoption amongst various school districts, military units, and institutional buyers, where early administration of medical oxygen in respiratory emergencies can often save a trip to the hospital. The Model 615 recently received CE Mark approval, a critical step toward launching this unique product into the 30 countries belonging to the European Economic Area.

Napodano further commented, "With an improved liquidity and less debt, we believe OxySure now has enough cash to fund operations into the third quarter 2014. By that time, we believe the company could be posting break-even operations."

The report further states that for 2015, OxySure could post revenues of $5 million.

The company currently trades at $0.78, and with 26 million shares outstanding, the company is capitalized at $20.3 million.

For more information about OxySure, please visit the company's website Investor relations is handled by Stonegate Securities, which can be reached at 214-987-4121 or by email at

About InvestmentPitch, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing corporate interviews and three minute videos based on news releases and research reports. Please visit and browse our extensive library of investment videos.

Barry Morgan, CFO

More Info:

This news is published on the Newswire and its syndicated partner network

Publish Your News - Send a release
News now!

Get free news alerts: Sign up here

Published at the Newswire - Big ideas for Global Investors

Disclaimer/ Disclosure:The newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info:

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

Free News Alerts


Investor Ideas © 2000 - 2014®, ECON

Sign up here

login | logout | about us | contact | disclaimer / disclosure |
advertise | company profile directory | partners / links |
job search | privacy policy | trade | services | sitemap |